ZENTALIS PHARMACEUTICALS INC. - COMMON STOCK

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 فبراير 2025 17:42:06 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

29 يناير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

28 يناير 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

09 يناير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 يناير 2025 16:53:30 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Key Management Appointments

12 ديسمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 ديسمبر 2024 16:35:10 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib

13 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 نوفمبر 2024 19:04:44 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

16 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

09 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 سبتمبر 2024 16:40:50 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress

09 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 أغسطس 2024 18:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 يوليو 2024 18:00:47 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program

18 يونيو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 يونيو 2024 18:00:55 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

30 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors

29 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting

23 مايو 2024 17:01:39 بحسب Nasdaq GlobeNewswire